Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Down 5.8% – What’s Next?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s share price dropped 5.8% on Wednesday . The company traded as low as $12.8955 and last traded at $12.9945. Approximately 323 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 11,785 shares. The stock had previously closed at $13.80.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company has an average rating of “Hold”.

Santen Pharmaceutical Price Performance

The business has a 50 day simple moving average of $12.23 and a 200 day simple moving average of $11.41. The company has a market cap of $4.19 billion and a price-to-earnings ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.